Category Archives: Transhuman News

What is Psoriasis?

Psoriasis is a chronic disorder causing red, scaly patches on the skin. It usually occurs on the limbs, trunk, and scalp but can show up on other parts of the body as well. It is not contagious but it can flare up causing the symptoms to get worse. The rash associated with psoriasis goes through cycles of improvement before it gets worse. Psoriasis is usually the result of a problem with the immune system. It is most likely to occur in members of the same family. At times, psoriasis can be disfiguring, uncomfortable, and even painful.

Symptoms of psoriasis appear as red, thickened areas of the skin with silvery scales. It most often appears on the scalp, elbows, knees, legs, arms, genitals, nails, palms, and lower back. The skin usually replaces itself after about a month. When psoriasis is present, the process speeds up and the skin is replaced in 3-4 days causing the skin cells to multiply quickly and accumulate on the surface in silvery scales. Psoriasis comes in many forms. Each differs in severity, duration, location, shape, and pattern of the scales. The most common form, called plaque psoriasis, begins with little red bumps. Gradually these become larger, and scales form.

Unfortunately, there is no cure for psoriasis but there are many different psoriasis treatments available that can clear the symptoms and bring relief. Your doctor may prescribe medications applied directly to the skin. These contain cortisone compounds, synthetic vitamin D analogs, retinoids, tar, or anthralin used to ease the discomfort caused by the skin patches. Other types of treatment include coal tar, Goeckerman treatment, light therapy, ultraviolet light B (UVB), PUVA, methotrexate, cyclosporine, and biologic agents. Controlling triggers that bring on bouts of psoriasis, such as stress, and taking care of your skin will help keep symptoms in control. The goal is to reduce inflammation and to control shedding of the skin. Moisturizing creams and lotions loosen scales and help control itching.

Visit link:
Psoriasis Specialist - Katy, TX & Cypress, TX: Texas ...

Psoriasis and psoriatic arthritis are both autoimmune disorders: They result from the immune system mistakenly attacking the body. Another autoimmune disorder, Hashimotos thyroiditis, can cause hypothyroidism.

Doctors and researchers believe that a person with one autoimmune condition, such as psoriasis or psoriatic arthritis, may have a higher likelihood of developing another autoimmune condition, such as Hashimotos thyroiditis.

Also known as Hashimotos disease, this condition causes the immune system to attack the thyroid gland, preventing it from making enough thyroid hormone. Hypothyroidism refers to having too little thyroid hormone in the body.

Below, learn more about the relationship between these autoimmune disorders.

Psoriasis is an autoimmune disorder that causes scaly, itchy patches of skin to form around a persons trunk, large joints, and other areas of the body. It affects about 24% of the population.

Psoriatic arthritis is a type of arthritis that can occur in people with psoriasis. About 30% of people with psoriasis also develop this form of arthritis. It is not possible to have psoriatic arthritis without psoriasis.

This inflammatory type of arthritis causes symptoms such as joint pain, swelling, and stiffness. If a person does not receive treatment, psoriatic arthritis can eventually lead to joint damage and mobility issues.

Hypothyroidism occurs when the thyroid gland does not make enough thyroid hormone to meet the bodys needs. The body uses this hormone to keep the brain, heart, and muscles functioning correctly. It also helps the body effectively burn calories for energy and warmth.

There are various causes of hypothyroidism, including Hashimotos disease, surgical removal of the thyroid gland, and other treatments for other health issues.

Hypothyroidism is not closely associated with psoriasis generally or psoriatic arthritis in particular. However, research indicates that a person with psoriasis may have a higher chance of developing hypothyroidism.

A 2017 study found that people with both psoriasis and psoriatic arthritis had a higher likelihood of developing this thyroid condition.

Another study from 2017 and one from 2018 found similar results: People with psoriasis had a higher likelihood of developing thyroid disease, such as hypothyroidism, compared with the general population.

Also, a 2019 review of studies found that people with psoriasis had a much higher prevalence of Hashimotos disease than those without psoriasis.

While there is a need for more studies with more participants, many researchers currently recommended that doctors regularly screen people with psoriasis for thyroid conditions.

Psoriasis and psoriatic arthritis are autoimmune conditions. While having psoriasis may increase the chances of developing hypothyroidism, one condition is not a sign of the other.

The American Thyroid Association report that common symptoms of hypothyroidism include:

These symptoms are relatively nonspecific and can stem from various causes. If a person experiences these symptoms, the doctor can check for hypothyroidism with a simple blood test.

If a person has hypothyroidism, the doctor prescribes a synthetic version of thyroid hormone. This medication should not affect psoriasis or psoriatic arthritis.

However, as the American Academy of Dermatology Association note, other medications can trigger new or worsening psoriasis symptoms, in periods called flare-ups.

If a medication has this effect, psoriasis symptoms typically get worse after about 23 weeks of starting the medication.

Some medications that may trigger a flare-up include:

Speak with a doctor before trying a new treatment, and let the doctor know if psoriasis symptoms worsen or new ones appear.

Myxedema is a skin condition that occurs in relation to advanced hypothyroidism. It develops when a person has the thyroid disorder and does not receive treatment for a long period.

A myxedema rash does not resemble psoriasis. Instead, it appears as waxy, swollen, thickened areas of skin.

Without medical intervention, myxedema can cause a life threatening coma. Anyone who may have this issue should receive prompt medical care.

Anyone with psoriatic arthritis or another form of psoriasis should speak with a doctor about the risk of developing another autoimmune disorder, such as Hashimotos disease.

Also, let the doctor know about any new or worsening psoriasis symptoms or symptoms of hypothyroidism.

In addition, contact the doctor if treatments are no longer controlling the symptoms. The doctor can adjust the treatment plan accordingly.

Research suggests a potential link between psoriasis, including psoriatic arthritis, and hypothyroidism. However, having psoriasis does not guarantee that hypothyroidism will also develop.

Work closely with a doctor to treat any form of psoriasis and let them know if any symptoms of an underactive thyroid develop.

Excerpt from:
Is there a link between psoriatic arthritis and hypothyroidism? - Medical News Today

Psoriasis is a common and commonly misunderstood disorder. Its not simply itchy, dry skin; according to the National Psoriasis Foundation (NPF), its caused by an immune-system dysfunction that brings on inflammation. Normally, a persons skin cells grow and shed in about a month, but for a person with psoriasis, that process is sped up, taking only about 3 or 4 days, and the result is a build-up of skin cells causing scales and plaque. About 8 million Americans deal with its discomfort every day, says the NPF.

Psoriasis is not curable, but thankfully its very treatable, says Mona Gohara, MD, associate clinical professor of dermatology at the Yale School of Medicine. Theres no need to endure the psychological or physical discomfort that may come along with this conditionseek treatment for it. There are a range of possible treatments, from topical creams and lotions to prescription oral medications. If you start at the bottom of therapeutic pyramid with creams, this may be enough to quell the irritation, says Dr. Gohara.

Some creams and lotions that can ease the dryness and itch are available over the counter; with others, youll need a prescription from a doctor. It takes a bit of trial and error to find what topical treatment may work best for you. Here, some guidance to the most common types of creams and lotions for psoriasis.

This is the active ingredient (approved by the FDA for treating psoriasis) in treatments that can help banish scales by softening them and making the outer layer of skin shed. You can find salicylic acid in many forms (not just lotions/creams/ointments, but also foams, soaps, gels, patches, and more). These treatments are designed to work in combo with others, because getting rid of the scales can help other treatments do their work more efficiently. If its a strong version, salicylic acid can irritate the skin and make hair more likely to break off, and that can lead to temporary hair loss, says the NPF.

The NPF says that these are the most frequently used treatments for psoriasis. Theyre designed to quell inflammation and pump the brakes on the growth of skin cells (this helps sidestep the buildup that produces scales). Steroid treatments come in different strengths; mild ones are available over the counter (OTC) and stronger types require a prescription. Generally, the stronger ones are needed for elbows, knees, and other hard to treat areas. These are powerful meds with potential side effects (thin skin, broken blood vessels, and more) and should be used carefully under a medical doctor's supervision. Also,the use of topical steroids on brown skin can create lightening, which may take time to repigment, says Dr. Gohara. Its always important to apply steroids directly on, not all around, lesions or areas of concern.

The NPF advises not to use a topical steroid for longer than three weeks without consulting a doctor, as well as to avoid stopping the use of one suddenly because that can cause a flare-up of your psoriasis. Another reason to use these under the care of a physician: Topical steroids can be absorbed via the skin and have an impact on internal organs when used for a long period of time or over a wide area of skin.

These prescription treatments also come in various forms not just creams, lotions and ointments, but also gels, foams, and more. In some medications, vitamin D is combined with a steroid. Like other treatments, meds with vitamin D slow down the pace of your skin cells' growth. (Depending on the specific medication, side effects can include skin irritation, stinging, burning, itching or excessive calcium in the urine.) One advantage of vitamin D creams is they dont run the risk of causing skin atrophy a very real side effect of chronic topical steroid use, says Dr. Gohara. But they can be more irritating. Generally, systemic side effects are rare, yet hypercalcemia is a theoretical risk, and your doctor may opt to have you get blood tests.

Vitamin A treatments

A topical retinoid, vitamin A is the active ingredient in prescription medication that comes in the form of a cream, gel, or foam. It also works by slowing the growth of skin cells. When using it, the plaques of psoriasis may turn bright red before clearing up. Side effects here also include skin irritation; the medication increases the risk of sunburn as well, so its critical to use sunscreen to protect your skin when using these meds.

Coal tar

This ingredient is found in different strengths in various treatment forms, including shampoo. It can be found in OTC products in its weaker strength and by prescription for stronger versions. Like other products, coal tar slows the growth of skin cells, but it can be stinky and irritating, and can stain your bedding and clothes (as well as blond hair).

Heres one of the challenging things about treating psoriasis: Your body can build up a tolerance to a certain medications, so something that seemed magical in its ability to bring you relief could suddenly stop working. On the other hand, a treatment that didnt work for you years ago could suddenly work wonders.

Thats why trial and error is a necessary part of psoriasis treatment. Finding the right treatment for psoriasis is much like finding the right partner. It may take some 'dating' until the right one finally comes along, says Dr. Gohara. Some may work for a bit, but then efficacy fizzles. Topical steroids are the most common culprit of this phenomenon, although it may happen with other topical or systemic medication as well.

According to the National Psoriasis Foundation, its key to moisturize daily it can lessen the itchy redness. They recommend that you use fragrance-free products and soaps that moisturize rather than dry you out, skip the way-hot shower (keep it lukewarm), and rub on moisturizer right after showering. The NPF recommends these OTC creams, based on information theyve heard from dermatologists while emphasizing that none of them are stand-ins for treatment from a healthcare provider. Still, theyre all deeply moisturizing and may improve some pesky symptoms such as flaking and itching:

Anti-Itch Concentrated Lotion with Calamine and Triple Oat Complex

This creamhas anti-inflammatory and antioxidant ingredients.

Moisturizing Cream for Psoriasis

CeraVe developed this with dermatologists to moisturize skin and rebuilt the skin barrier.

Hydra Therapy, Itch Defense Moisturizer

A shea butter lotion, it's designed to be used right after a shower.

Psoriasis Medicated Treatment Gel

$42.29

This gelhas salicylic acid to work on scales, itching, and dryness.

Skin Calming Intensive Itch Relief Lotion

With menthol and oatmeal, the lotion is especially good for nighttime itching, according to the manufacturer.

Ultimate Multi-Symptom Psoriasis Relief Cream

$25.90

A soothing cream with salicylic acid and a bunch of moisturizers.

Intense Skin Repair Body Lotion

$28.48

The manufacturer says this deeply moisturizing lotion lasts for 24 hours to help repair skin.

Medicated Moisturizing Psoriasis Cream

A salicylic acid cream that also contains aloe and shea butter.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Go here to see the original:
The Best Creams for Psoriasis - Over-the-Counter and ...

BARCELONA, Spain and COPENHAGEN, Denmark, Feb. 17, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora Cream. Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25 million units in sales volume annually2. The market represents a significant opportunity for Wynzora Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than $300 million.2

Wynzora Cream (50 g/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020. Wynzora Cream is currently under review in Europe supported by two Phase 3 trials1, including an EU head-to-head trial against active comparator Dovobet/Daivobet Gel. The Physician Global Assessment (PGA) treatment success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for Wynzora Cream vs. 6% for vehicle (p<0.0001). The treatment satisfaction score using the Psoriasis Treatment Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet Gel. Using MC2 Therapeutics' PAD Technology, Wynzora Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining the three essentials of a topical therapy in one single product namely high efficacy, a favorable safety profile and convenience of use.

Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with this agreement with MC2 Therapeutics. Wynzora Cream has demonstrated significant improvements in the skin clearance of psoriasis patients. It is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment options, covering the whole spectrum of the disease. We are delighted that soon we will be able to offer this novel topical treatment to European dermatologists and their patients."

Jesper J. Lange, CEO of MC2 Therapeutics, commented: "We are excited to partner with Almirall, an established company with deep expertise in dermatology and psoriasis and with the focus to improve patients' needs. Bringing together Almirall's excellence in commercial operations and MC2 Therapeutics' commitment to ensure a global roll-out of Wynzora Cream we will, upon approval, ensure a strong launch of Wynzora Cream for the benefit of the many patients living with plaque psoriasis and for the healthcare practitioners who provide care. We believe that the unique combination of compelling clinical efficacy, a favorable safety profile and treatment convenience are key components to treatment adherence and overall better patient satisfaction in topical treatment of plaque psoriasis in a real-world setting."

About Plaque Psoriasis Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. Psoriasis affects people of all ages, and in all countries. The reported prevalence of psoriasis in Europe varies from 0.6% to 6.5% with an average of approximately 3% of the population3,4making psoriasis a serious global problem with more than 100 million individuals affected worldwide.5The flares of psoriasis can be unpredictable and significant comorbidities are common, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.4

About Wynzora CreamWynzora Cream (50 g/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) is under review in Europe as a topical treatment of plaque psoriasis in adults. Wynzora Cream is based on PAD Technology, enabling an aqueous cream formulation of both calcipotriol and betamethasone as dipropionate and optimal delivery of active ingredients into the target tissue. Wynzora Cream was approved in the US by the FDA on 20th July 2020.

References:1Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov 2IQVIA MIDAS 3Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis', J. Autoimmune, 34: J314-J21 4Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37 5WHO Global report on Psoriasis 2016

SOURCE Almirall, S.A.

Read the original here:
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora Cream for treatment of...

Psoriasis treatment marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 15.09 billion by 2027 growing with the CAGR of 7.35% in the above-mentioned forecast period. Not having any specific effective and leading treatment will help in driving the growth of the psoriasis treatment market.

Psoriasis treatment market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriasis-treatment-market&kb

The major players covered in the psoriasis treatment market report are Eli Lilly & Company, Pfizer Inc., Janssen Global Services LLC, Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis International AG, Amgen Inc., Biogen Inc., Abbvie Inc., AstraZeneca, Boeringer Ingelheim International GmbH, Biogen, Johnson & Johnson Services Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB S.A., LEO Pharma, Cipla Inc., Rowan Bioceuticals, Glenmark Pharmaceuticals, and Win-Medicare Pvt. Ltd., among other domestic and global players.

Global Psoriasis Treatment Market Scope and Market Size

Psoriasis treatment market is segmented on the basis of drug class, type, route of administration, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psoriasis-treatment-market&kb

Key questions answered in the Global Psoriasis treatment Market report include:

Table of Contents:

Request for Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-psoriasis-treatment-market&kb

Major Insights of the Report

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Global Psoriasis Treatment Market Including Business Growth Statistics, New Opportunities And Competitive Outlook By Celgene Corporation, Takeda...

Phototherapy Device Market: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/phototherapy-device-market.html

Key Drivers, Restrains, and Opportunities of Global Phototherapy Device Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81376

Request for Analysis of COVID-19 Impact on Phototherapy Device Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81376

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81376

North America to Capture Major Share of Global Phototherapy Device Market

Pre Book Phototherapy Device Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=81376&ltype=S

Key Players Operating in Global Phototherapy Device Market

The global phototherapy device market is highly consolidated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Demand for products to treat diseases is increasing in emerging as well as developed markets. Growth strategies adopted by leading players are likely to drive the global phototherapy device market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Link:
Phototherapy Device Market: Rising prevalence of skin diseases is expected to drive the market - BioSpace

For many years, researchers have had difficulties decoding why skin diseases such as psoriasis and eczema affect some people more than others, why some patient develop comorbidities and why some patients do not respond to treatment. A new research programme including a biobank is about to change that by elucidating how skin diseases develop in patients over time. Such new knowledge is critical in order to develop new treatments tailored for each patient.

The goal is to collect data from 3,000 patients with skin diseases and in the long term also making data and knowledge available for researchers around the world.

We are setting up a new research programme with clinical data, blood and skin samples from 3,000 patients, which shall help us understand the widespread diseases psoriasis and eczema. We follow the patients continuously over time, which will give us unique data and new insights. Such a biobank simply does not exist anywhere else, says Charlotte Bonefeld, Acting Executive Director and Professor at the LEO Foundation Skin Immunology Research Center at the University of Copenhagen.

The research programme and the biobank is a collaboration between the LEO Foundation Skin Immunology Research Center at the University of Copenhagen and the Department of Dermatology and Allergy at Herlev and Gentofte Hospital. The LEO Foundation has supported the programme with DKK 40 million.

About the grant

The research programme will be established by the LEO Foundation Skin Immunology Research Center at the University of Copenhagen and the Department of Dermatology and Allergy at Herlev and Gentofte Hospital. The programme is supported with DKK 40 million from the LEO Foundation and co-financed with DKK 20 million from Herlev and Gentofte Hospital and LEO Foundation Skin Immunology Research Center.

Close collaboration between clinical and basic researchers across hospital and university is at the core of the research programme. Together with close contact to patients through patient associations, the interdisciplinary collaboration will ensure the relevance and impact of the research for the patients.

Our close collaboration between basic and clinical researchers provides a unique opportunity to gather patient information, skin and blood samples from the same patient over several years and will make it possible to conduct new research that will lead to more effective treatments, says Lone Skov, Clinical Professor and Chief Physician at Herlev and Gentofte Hospital.

The biobank will be a valuable asset in the future as the centre and partners from all over the world will be able to access a comprehensive archive of samples and data of the highest quality. This will have a major impact on how quickly we can translate ideas into concrete results, adds Lone Skov.

The recruitment of patients to the research programme will begin in 2021.

Top research facilities

The establishment of the new research programme also emphasises that the LEO Foundation Skin Immunology Research Center will continue to be a world-class skin research centre. The centre shall both be a base for leading researchers in skin diseases and be able to support the collaboration between basic research and the clinical environments at the hospitals.

Skin diseases

3-4 per cent of all people in Northern Europe suffer from psoriasis.

3-5 per cent of adults and 15 per cent of children suffer from atopic dermatitis.

15 per cent of adults have contact dermatitis.

In order to achieve that goal, top research facilities and infrastructure are crucial. And that is exactly what the new research programme will be contributing to.

Jesper Mailind, Chief Executive Officer of the LEO Foundation, is looking forward to following the new research programme.

Skin diseases represent a major problem for many people in their everyday lives. That is why it is important to increase our collective knowledge about skin diseases. With the new biobank, the LEO Foundation Skin Immunology Research Center has a unique possibility to strengthen collaboration between clinical and basic research within immunology, skin and skin diseases and to collect new knowledge which can in turn pave the way for new treatments of psoriasis and eczema, he says.

See the rest here:
University of Copenhagen: Skin tissue samples from 3,000 patients to give researchers new insights into psoriasis and eczema - India Education Diary

This article was originally published here

Front Med (Lausanne). 2021 Feb 2;8:585634. doi: 10.3389/fmed.2021.585634. eCollection 2021.

ABSTRACT

Background: Although there have been many epidemiological studies, research focusing on psoriasis health burden on a global scale is still lacking. Trends and variations in the global health burden of psoriasis are evaluated by time, age, gender, geographical location, and socioeconomic status, using disability-adjusted life years (DALYs) from the Global Burden of Disease Study. Methods: The health burden of psoriasis was evaluated by DALYs, which combined years lost to disability (a morbidity component) with years of life lost (a mortality component). The global and national DALYs number, crude DALYs rate, and age-standardized DALYs rate were obtained from the GBD 2017 study database. The corresponding human development index (HDI) was collected from the United Nations Development Programme. Results: From 1990 to 2017, the DALYs number and crude DALYs rate due to psoriasis increased by 73 and 22%, respectively. In comparison, the age-standardized DALYs rate showed a slight increase. Patients in the age range of 65-69 years bear a more significant psoriasis burden. Both males and females showed an increasing trend in burden caused by psoriasis over the past 27 years, with females bearing a more significant psoriasis burden than males. The health burden of psoriasis was substantially unequal in geography with a Gini coefficient of 0.27. The concentration indexes indicated a socioeconomic associated inequality in psoriasis burden with values of 0.22, accounting for 48.64% variance across countries (R2 = 0.4864, p < 0.001). Between-nation inequality in the distribution of psoriasis burden continued to decline throughout the past 27 years. Gini coefficients of psoriasis burden decreased from 0.280 in 1990 to 0.265 in 2017. The concentration indexes indicated the same trend with 0.236 in the 1990s and 0.223 in 2017. Conclusions: Global health progress in psoriasis together with inequality in the past few decades. Although the inequality of psoriasis burden has shown some improvement during the past 27 years, disparities still exist in age, gender, geographical location, as well as socioeconomic status. The findings of this study highlight the global importance of psoriasis and is important in policy planning for psoriasis services on a global scale.

PMID:33604344 | PMC:PMC7884455 | DOI:10.3389/fmed.2021.585634

The rest is here:
Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends From 1990 to 2017 - DocWire News

Data Bridge Market Research Adds Global Psoriasis Market Industry Trends and Forecast to 2028 new report to its research database. The report spread No of pages : 350 No of Figures: 60 No of Tables: 220 in it. This comprehensive Global Psoriasis Market industry research report includes a brief on these trends that can help the organizations operating in the industry to understand the market and strategize for their business expansion accordingly. The research report analyzes the market CAGR,Volume, industry share And size, demand and trend growth, key segments, and key drivers and restrains.

New Players in the market are facing tough competition from established international Players as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

Global psoriasis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriasis-market

Competitive Landscape and Global Psoriasis Market Share Analysis

Global psoriasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global psoriasis market.

The major players covered in the global psoriasis market are Novartis AG, Pfizer Inc., Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Abbvie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Johnson & Johnson Services, Inc, AstraZeneca and others.

Rise in prevalence of psoriasis due to changing lifestyle and rise in cases of immune diseases are responsible for growth of psoriasis market. Moreover, growing awareness about the treatment may also boost the growth of this market. However, lack and effective medication for treatment may restrain the market growth.

Psoriasis is an inflammatory skin condition in which life cycle of skin cell speeds up, which causes skin cells to build up on skin surface. The common symptoms of psoriasis are red patches on skin, itching and burning sensation and others. Psoriasis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

This Global Psoriasis Market Research/analysis Report Focus on following important aspects:Global Psoriasis Market

Key Developments in the Market: Global Psoriasis Market

However, high cost of Psoriasis products is one of the key factors which are expected to limit the growth of global Psoriasis market over the forecast period.

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Psoriasis Market Landscape

Part 05: Market Sizing

More TOC Continue

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-psoriasis-market

Global Psoriasis Market Scope and Market Size

Psoriasis market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel.

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psoriasis-market

Global Psoriasis Market Country Level Analysis

Psoriasis market is analyzed and market size information is provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global psoriasis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Asia-Pacific is expected to contribute for the largest share in the market the market due to the increasing population. Europe is considered to hold bright growth prospects in the coming years with growing investment in healthcare infrastructure. North America region is likely to lead the market for psoriasis market due to focus of global key market players on novel technology.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global psoriasis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Global Psoriasis Market Trends and Vendors Analysis after Covid-19 Pandemic Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 ...

This article was originally published here

Med Hypotheses. 2021 Feb 10;149:110530. doi: 10.1016/j.mehy.2021.110530. Online ahead of print.

ABSTRACT

Hidradenitis Suppurativa (HS) is a chronic, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. The pathophysiology of the disease remains elusive, with newer therapies targeting various aspects of the dysregulated immune system. This presents a useful opportunity to look at the cytokine profile in HS and other inflammatory conditions that share similar patterns with the aim of teasing out less considered explanations for HS pathogenesis. It has been observed that IL-17 appears to be the most common denominator linking HS with other immune mediated diseases like Crohn, ulcerative colitis, multiple sclerosis and psoriasis. Given that IL-17 plays an important role in antifungal immunity, evidenced by the cytokine pattern in fungal disease and the bulk of data citing their potential involvement in Crohn, ulcerative colitis, multiple sclerosis and psoriasis; it is fair to suggest the need to explore the role that fungi play in the setting of HS going forward. The aryl hydrocarbon receptor (ahr) is a ubiquitous and largely conserved entity that is gaining interest in inflammatory conditions such as psoriasis and atopic dermatitis. It is well known to modulate autoimmune states. Its activation by both exogenous and endogenous agents result in secretion of IL-17 by Th17 cells. One of such agents is the tryptophan metabolite 6-formylindolo [3,2-b] carbazole (FICZ)-which can be produced by microorganisms such as fungi. It will be interesting to explore its usefulness in HS pathogenesis.

PMID:33607406 | DOI:10.1016/j.mehy.2021.110530

See the original post:
Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology - DocWire News